Maxigen Biotech Inc - Asset Resilience Ratio
Maxigen Biotech Inc (1783) has an Asset Resilience Ratio of 0.09% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Maxigen Biotech Inc (1783) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2009–2024)
This chart shows how Maxigen Biotech Inc's Asset Resilience Ratio has changed over time. See 1783 net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Maxigen Biotech Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 1783 stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$1.50 Million | 0.09% |
| Total Liquid Assets | NT$1.50 Million | 0.09% |
Asset Resilience Insights
- Limited Liquidity: Maxigen Biotech Inc maintains only 0.09% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Maxigen Biotech Inc Industry Peers by Asset Resilience Ratio
Compare Maxigen Biotech Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Gan & Lee Pharmaceuticals Co Ltd
SHG:603087 |
Medical Instruments & Supplies | 9.08% |
|
Vizionfocus Inc.
TW:4771 |
Medical Instruments & Supplies | 5.07% |
|
Ansell Ltd
AU:ANN |
Medical Instruments & Supplies | 4.42% |
|
Nanosonics Ltd
AU:NAN |
Medical Instruments & Supplies | 51.82% |
|
SDI Ltd
AU:SDI |
Medical Instruments & Supplies | 6.36% |
|
Austco Healthcare Ltd
AU:AHC |
Medical Instruments & Supplies | 15.90% |
|
Trajan Group Holdings Ltd
AU:TRJ |
Medical Instruments & Supplies | 0.23% |
|
Osteopore Ltd
AU:OSX |
Medical Instruments & Supplies | 43.09% |
Annual Asset Resilience Ratio for Maxigen Biotech Inc (2009–2024)
The table below shows the annual Asset Resilience Ratio data for Maxigen Biotech Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.09% | NT$1.50 Million ≈ $47.26K |
NT$1.58 Billion ≈ $49.86 Million |
-0.01pp |
| 2023-12-31 | 0.10% | NT$1.50 Million ≈ $47.26K |
NT$1.49 Billion ≈ $47.04 Million |
-0.61pp |
| 2022-12-31 | 0.71% | NT$10.32 Million ≈ $325.01K |
NT$1.45 Billion ≈ $45.61 Million |
-1.41pp |
| 2021-12-31 | 2.12% | NT$26.87 Million ≈ $846.62K |
NT$1.27 Billion ≈ $39.86 Million |
+0.75pp |
| 2020-12-31 | 1.37% | NT$13.13 Million ≈ $413.82K |
NT$956.47 Million ≈ $30.13 Million |
-12.55pp |
| 2019-12-31 | 13.92% | NT$165.05 Million ≈ $5.20 Million |
NT$1.19 Billion ≈ $37.35 Million |
-6.53pp |
| 2018-12-31 | 20.45% | NT$232.25 Million ≈ $7.32 Million |
NT$1.14 Billion ≈ $35.77 Million |
+9.31pp |
| 2017-12-31 | 11.15% | NT$123.05 Million ≈ $3.88 Million |
NT$1.10 Billion ≈ $34.78 Million |
-12.37pp |
| 2016-12-31 | 23.52% | NT$258.07 Million ≈ $8.13 Million |
NT$1.10 Billion ≈ $34.57 Million |
+4.13pp |
| 2015-12-31 | 19.39% | NT$226.53 Million ≈ $7.14 Million |
NT$1.17 Billion ≈ $36.81 Million |
-23.56pp |
| 2014-12-31 | 42.95% | NT$435.41 Million ≈ $13.72 Million |
NT$1.01 Billion ≈ $31.94 Million |
+11.95pp |
| 2013-12-31 | 31.00% | NT$314.50 Million ≈ $9.91 Million |
NT$1.01 Billion ≈ $31.96 Million |
+23.83pp |
| 2012-12-31 | 7.17% | NT$36.26 Million ≈ $1.14 Million |
NT$505.76 Million ≈ $15.93 Million |
-4.97pp |
| 2011-12-31 | 12.14% | NT$59.09 Million ≈ $1.86 Million |
NT$486.65 Million ≈ $15.33 Million |
+11.95pp |
| 2010-12-31 | 0.19% | NT$820.00K ≈ $25.83K |
NT$429.76 Million ≈ $13.54 Million |
-0.93pp |
| 2009-12-31 | 1.12% | NT$3.85 Million ≈ $121.36K |
NT$343.55 Million ≈ $10.82 Million |
-- |
About Maxigen Biotech Inc
Maxigen Biotech Inc. researches, develops, produces, and sells implantable medical devices and cosmetic products in Taiwan, America, Europe, rest of Asia, and internationally. It operates through two segments, Biomedical Products and Consumer Products. The company provides biomedical materials, such as collagen and bone materials; beauty care products; and medical devices for ophthalmology, otola… Read more